Holder snapshot 7 signals
Share change
+3,984,660
Put/Call ratio
2772%
SEC-reported price per share
$28.44
Indexed holders
135
Value change
+$122,882,388
Number of buys
67
Open additional details 1 more signal available
Number of sells
54
Security identity Names, identifiers, and filing context for this profile. 1 source field
Shares outstanding
123,305,030

Security key

N62509109

Report period

Q3 2025

Indexed institutions

135

Top holders

10

Ownership snapshot

Top reported holders of NAMS - NewAmsterdam Pharma Co N.V. - Ordinary Shares, nominal value EUR 0.12 per share (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader
Forbion Capital Fund IV C...
Disclosed value leader
Frazier Life Sciences Man...
Comparable rows
1/15
Latest evidence
26 Sep 2025
13D/G 3/4/5 13F Lead comparable stake: 8.3% 14 rows are not safely comparable across share classes. 13D/G row: Forbion Capital Fund IV Cooperatief U.A. Showing 1-6 of 15 holder rows.

Quick read

Forbion Capital Fund IV Cooperatief U.A. leads the comparable SEC ownership view at 8.3%.

1 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens Forbion Capital Fund IV Cooperatief U.A.'s linked filing trail.
Comparable ownership Top 1
Forbion Capital Fund IV Cooperati... 8.3%

Ownership % is shown only when SEC disclosures are safely comparable across share classes.

Detailed SEC evidence table Showing 1-6 of 15 holder rows
Holder Evidence Ownership % Position 12M Net Δ As of
Forbion Capital Fund IV Cooperatief U.A.
13D/G
ForGrowth NAP B.V.
8.3%
Reported 13D/G · 26 Sep 2025
$223,140,090
9,316,914 shares
-$30,222,313 26 Sep 2025
ForGrowth NAP B.V.
3/4/5
10%+ Owner
—
denominator unverified
$272,125,599
10,656,172 shares
— 30 Dec 2024
Bain Capital Life Sciences Investors, LLC
3/4/5 13F
10%+ Owner · Company
—
mixed-class rows
$239,004,182
12,106,566 shares
mixed-class rows
— 13 Dec 2024
Frazier Life Sciences Management, L.P.
13F
Company
13F
—
mixed-class rows
$304,756,774
17,107,407 shares
mixed-class rows
— 30 Jun 2025
FCPM III SERVICES B.V.
13F
Company
13F
—
denominator unverified
$192,547,567
10,632,113 shares
— 30 Jun 2025
RA CAPITAL MANAGEMENT, L.P.
13F
Company
13F
—
mixed-class rows
$186,282,831
10,472,271 shares
mixed-class rows
— 30 Jun 2025
How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

13F holder rows

Institutional holders as of Q3 2025

Investor-level positions for this CUSIP, loaded as an interactive table.

Indexed institutions
135
Shares
120,390,588
Indexed holders
135
Investor Option Weight % Change % SEC-reported value * Price Shares Share Change Activity Report Period

* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.

Reported share positions only; options and principal amounts are excluded. Missing manager disclosures are unavailable, not zero. A missing position becomes zero only when complete coverage is verified for both snapshots. Counts describe the indexed universe; the comparison may cover a smaller set.

Compare Q3 2025 vs Q2 2025 Across Filers

Q2 2025 indexed holders
130
Q3 2025 indexed holders
135
Indexed holder difference
5
Investor Q2 2025 Shares Q3 2025 Shares Share Diff Share Chg % Q2 2025 value Q3 2025 value Value change Value Chg %

Trend: the last eight indexed quarters, including the selected comparison periods.

Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .